Skip to main content
Pangen Biotech Inc. logo

Pangen Biotech Inc. — Investor Relations & Filings

Ticker · 222110 ISIN · KR7222110009 KO Manufacturing
Open in API
Filings indexed 333 across all filing types
Latest filing 2020-06-30 Share Issue/Capital Cha…
Country KR South Korea
Listing KO 222110

About Pangen Biotech Inc.

https://pangen.com/layout/eng/home.php

Pangen Biotech Inc. is a biotechnology company specializing in the research, development, and manufacturing of biopharmaceuticals. The company utilizes its proprietary platform technologies, particularly those based on Chinese Hamster Ovary (CHO) cell lines, for the production of complex protein therapeutics. Its primary business activities include the development of a pipeline of biosimilar products, such as Erythropoietin (EPO) and Aflibercept. In addition to its own product pipeline, Pangen Biotech offers Contract Development and Manufacturing Organization (CDMO) services, providing expertise in cell line development and biopharmaceutical production to other firms. The company also supplies reagents and kits for research applications.

Recent filings

Filing Released Lang Actions
[기재정정]주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 100% confidence The document is a regulatory filing from Pangen Co., Ltd. titled '주식매수선택권 부여에 관한 신고' (Report on Granting of Stock Options) and specifically functions as a '정정신고' (Amendment Report) to a previously filed stock option grant. In the context of Korean financial regulatory filings (DART system), this type of disclosure regarding stock options, especially amendments to existing grants, falls under general regulatory filings as it does not fit into specific categories like M&A, dividends, or financial reports.
2020-06-30 Korean
[기재정정]최대주주변경을수반하는주식담보제공계약체결
Major Shareholding Notification Classification · 100% confidence The document is a regulatory filing from the Korean Exchange (KRX) system regarding a 'Pledge of Shares' (stock collateral agreement) by the company's largest shareholder. It details the modification of collateral terms, including changes in the collateral amount and duration. This type of disclosure, which involves the pledging of shares by major shareholders, is classified as a regulatory filing under the RNS category as it does not fit into specific categories like director dealings (which are usually personal trades) or share issues.
2020-06-22 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding of Stocks, etc.), which is a standard regulatory filing in South Korea under the Capital Markets Act (Article 147). This document tracks changes in share ownership by major shareholders and their special relations, including details on collateral contracts. It is a formal regulatory disclosure rather than an annual report, investor presentation, or simple announcement. Given the specific nature of reporting major shareholding thresholds, it falls under the 'Major Shareholding Notification' category.
2020-06-22 Korean
[기재정정]사업보고서 (2019.12)
Annual Report Classification · 95% confidence The document is a 'Correction Report' (정정신고) for a previously filed 'Business Report' (사업보고서), which is the Korean equivalent of an Annual Report (10-K). The document contains specific corrections to market data tables and includes the standard 'Confirmation by Representative Director' (대표이사 등의 확인) section. Since it is a formal correction to an existing Annual Report and contains substantive financial/business data, it is classified as an Annual Report (10-K). FY 2019
2020-05-13 Korean
분기보고서 (2020.03)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (분기보고서) for the company 'PanGen' (주)팬젠 for the period 2020.01.01 to 2020.03.31. It contains detailed financial information, business descriptions, capital changes, and management discussions, which are characteristic of a comprehensive quarterly financial report. It is not an announcement of a report, but the report itself. Q1 2020
2020-05-13 Korean
[기재정정]단일판매ㆍ공급계약체결
Regulatory Filings Classification · 95% confidence The document is a regulatory filing from a Korean company (Pangen) regarding a 'Correction Report' (정정신고) for a previously disclosed 'Single Sales/Supply Contract' (단일판매ㆍ공급계약체결). It details changes to the contract amount due to adjustments in pharmaceutical production volume. Since this is a specific regulatory disclosure regarding a commercial contract and does not fit into categories like M&A, dividends, or financial reports, it is classified as a general regulatory filing.
2020-05-12 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.